BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 11919233)

  • 21. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.
    Leonard GD; Wagner MR; Quinn MG; Grem JL
    Anticancer Drugs; 2004 Aug; 15(7):733-5. PubMed ID: 15269607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Kovats E; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2003 Apr; 21(7):1307-12. PubMed ID: 12663719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study.
    Banach M; Zygulska AL; Krzemieniecki K
    J Cancer Res Ther; 2018; 14(5):1010-1013. PubMed ID: 30197340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
    Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
    Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies.
    Krøigård T; Schrøder HD; Qvortrup C; Eckhoff L; Pfeiffer P; Gaist D; Sindrup SH
    Eur J Neurol; 2014 Apr; 21(4):623-9. PubMed ID: 24460946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
    Storey DJ; Sakala M; McLean CM; Phillips HA; Dawson LK; Wall LR; Fallon MT; Clive S
    Ann Oncol; 2010 Aug; 21(8):1657-1661. PubMed ID: 20089559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
    Carlomagno C; Orditura M; Pepe S; De Vita F; Romano C; Ciardiello F; Ferrara C; Martinelli E; Bianco R; Aurilio G; D'Agostino D; Tortora G; Catalano G; De Placido S
    Am J Clin Oncol; 2006 Feb; 29(1):85-9. PubMed ID: 16462509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
    Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
    Uña E
    J Oncol Pharm Pract; 2010 Dec; 16(4):280-2. PubMed ID: 20015928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Shields AF; Zalupski MM; Marshall JL; Meropol NJ
    Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.